
zzso is a growing health concern in Canada and the United States, and zzso therapies such as zzso are being more commonly prescribed to assist with weight zzso 

Our goal was to assess the efficacy and safety of zzso compared with either zzso or an active control with regard to weight loss and serum zzso changes in overweight zzso 

We performed a systematic literature search of zzso zzso through December 2003) and the Cochrane Central Register of Controlled zzso zzso trials and reviews were searched by zzso zzso trials comparing zzso and a control and reporting changes in weight loss, serum lipids zzso cholesterol, LDL cholesterol, HDL cholesterol, zzso and zzso or both in overweight and obese patients zzso mass index (in zzso or zzso were zzso 

zzso zzso trials met our inclusion zzso zzso studies including zzso patients compared 3 zzso 120 zzso zzso with zzso or an inactive control along with a zzso diet over a zzso zzso Relative risks zzso associated with clinically significant weight losses of zzso and zzso were zzso zzso zzso zzso zzso and zzso zzso zzso both favoring zzso Improvement in total cholesterol, LDL cholesterol, HDL cholesterol, and zzso were also greater with zzso zzso events were more common with zzso than with zzso zzso zzso zzso zzso 

Our findings suggest that 3 zzso 120 zzso zzso is effective for improving both weight loss and serum zzso profiles in obese patients at low and high cardiovascular disease risk and in obese patients with type 2 zzso 

